Evidence map›Paper›PMID 23794798›Full record

ArticleInfectious diseases2012

In Vivo Replication and Pathogenesis of Vesicular Stomatitis Virus Recombinant M40 Containing Ebola Virus L-Domain Sequences.

Takashi Irie, Elena Carnero, Adolfo García-Sastre, Ronald N Harty

Open access · goldAbstract read
In one paragraph

Article in Infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy.The journal of venomous animals and toxins including tropical diseases · 2015
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Takashi IrieDepartment of Virology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Elena Carnero
Adolfo García-Sastre
Ronald N Harty
Hiroshima University · JPUniversity of Pennsylvania · US

Funding

Technological Development ComponentU19AI062623 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI MORAN, THOMAS M · 2004 to 2009
$21.3M
Budding of Negative-sense RNA VirusesR01AI046499 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HARTY, RONALD N. · 2002 to 2006
$1.4M
Innate Immune Defenses Against Filoviruses.R21AI090284 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HARTY, RONALD N · 2010 to 2011
$437k
NIAID NIH HHS R01 AI046499NIAID NIH HHS R21 AI090284NIAID NIH HHS U19 AI062623
6 · The paper itself

Abstract

The M40 VSV recombinant was engineered to contain overlapping PTAP and PPxY L-domain motifs and flanking residues from the VP40 protein of Ebola virus. Replication of M40 in cell culture is virtually indistinguishable from that of control viruses. However, the presence of the Ebola PTAP motif in the M40 recombinant enabled this virus to interact with and recruit host Tsg101, which was packaged into M40 virions. In this brief report, we compared replication and the pathogenic profiles of M40 and the parental virus M51R in mice to determine whether the presence of the Ebola L-domains and flanking residues altered in vivo characteristics of the virus. Overall, the in vivo characteristics of M40 were similar to those of the parental M51R virus, indicating that the Ebola sequences did not alter pathogenesis of VSV in this small animal model of infection.

Indexed as

animal modelbuddingEbolaL-domainpathogenesisrecombinant virusVSV

Identifiers

PMID23794798
PMCPMC3686127
OpenAlexW2098182113

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.